{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:50:51Z","timestamp":1783335051397,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science Foundation of Guangdong Second Provincial General Hospital","award":["YY2018-002"],"award-info":[{"award-number":["YY2018-002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103906"],"award-info":[{"award-number":["82103906"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Evidence for the relationship between glycated hemoglobin (HbA1c) levels and risk of cardiovascular diseases (CVD) in patients with gout remained sparse and limited. This study aims to explore the associations between HbA1c levels and risks of incident CVD in patients with gout.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included patients with gout who had an HbA1c measurement at baseline from the UK Biobank. CVD events were identified from through medical and death records. We used multivariable Cox proportional hazards model with a restricted cubic spline to assess the potential non-linear effect of HbA1c on CVD risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included a total of 6,685 patients (mean age 59.7; 8.1% females) with gout for analyses. During a mean follow-up of 7.3\u2009years, there were 1,095 CVD events documented with an incidence of 2.26 events per 100 person-years (95% confidence interval [CI]: 2.13\u20132.40). A quasi J-shaped association between HbA1c and risk of CVD was observed, with the potentially lowest risk found at the HbA1c of approximately 5.0% (hazard ratio [HR]\u2009=\u20090.65, 95% CI: 0.53\u20130.81). When compared with the HbAlc level of 7%, a significantly decreased risk of CVD was found from 5.0 to 6.5%, while an increased risk was observed at 7.5% (HR\u2009=\u20091.05) and 8.0% (HR\u2009=\u20091.09). Subgroup analyses yielded similar results to the main findings in general.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on data from a nationwide, prospective, population-based cohort, we found a quasi J-shaped relationship between HbA1c and risk of CVD in patients with gout. More high-quality evidence is needed to further clarify the relationship between HbA1c and CVD risk in patients with gout.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01567-9","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T11:05:36Z","timestamp":1657883136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Associations between glycated hemoglobin and the risks of incident cardiovascular diseases in patients with gout"],"prefix":"10.1186","volume":"21","author":[{"given":"Likang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"2","key":"1567_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41584-021-00725-9","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022;18(2):97\u2013111.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"1567_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/rheumatology\/kez476","volume":"59","author":"Y Xia","year":"2020","unstructured":"Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, Xu X, Chang Q, Niu K, Zhao Y. Global, regional and national burden of gout, 1990\u20132017: a systematic analysis of the Global Burden of Disease Study. Rheumatology (Oxford). 2020;59(7):1529\u201338.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1567_CR3","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/art.41404","volume":"72","author":"S Safiri","year":"2020","unstructured":"Safiri S, Kolahi AA, Cross M, Carson-Chahhoud K, Hoy D, Almasi-Hashiani A, Sepidarkish M, Ashrafi-Asgarabad A, Moradi-Lakeh M, Mansournia MA, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990\u20132017: a systematic analysis of the global burden of disease study 2017. Arthritis Rheumatol. 2020;72(11):1916\u201327.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1567_CR4","doi-asserted-by":"publisher","first-page":"e58-e70","DOI":"10.1016\/S2665-9913(20)30221-6","volume":"3","author":"R Hansildaar","year":"2021","unstructured":"Hansildaar R, Vedder D, Baniaamam M, Tausche A-K, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021;3(1):e58\u201370.","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 1","key":"1567_CR5","first-page":"S83-S96","volume":"45","author":"C Practice","year":"2022","unstructured":"American Diabetes Association Professional, Practice C, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, et al. 6. glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83\u201396.","journal-title":"Diabetes Care"},{"key":"1567_CR6","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1744","author":"A Cahn","year":"2022","unstructured":"Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK. Association of baseline HbA1c with cardiovascular and renal outcomes: analyses from DECLARE-TIMI 58. Diabetes Care. 2022. https:\/\/doi.org\/10.2337\/dc21-1744.","journal-title":"Diabetes Care"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"108952","DOI":"10.1016\/j.diabres.2021.108952","volume":"178","author":"FL Zhou","year":"2021","unstructured":"Zhou FL, Deng MY, Deng LL, Li YM, Mo D, Xie LJ, Gao Y, Tian HM, Guo YK, Ren Y. Evaluation of the effects of glycated hemoglobin on cardiac function in patients with short-duration type 2 diabetes mellitus: a cardiovascular magnetic resonance study. Diabetes Res Clin Pract. 2021;178:108952.","journal-title":"Diabetes Res Clin Pract"},{"issue":"24","key":"1567_CR8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"G Study","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes, Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"key":"1567_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0084-3741(09)79331-X","volume":"2009","author":"S Schinner","year":"2009","unstructured":"Schinner S. Glucose control and vascular complications in veterans with type 2 diabetes. Yearbook Endocrinol. 2009;2009:2\u20133.","journal-title":"Yearbook Endocrinol"},{"issue":"Suppl 1","key":"1567_CR10","first-page":"S73-S84","volume":"44","author":"A American Diabetes","year":"2021","unstructured":"American Diabetes A. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73\u201384.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1567_CR11","first-page":"S119-S125","volume":"41","author":"A American Diabetes","year":"2018","unstructured":"American Diabetes A. 11. Older adults: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S119\u201325.","journal-title":"Diabetes Care"},{"issue":"6","key":"1567_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"1567_CR13","doi-asserted-by":"publisher","first-page":"e1-e20","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM, et al. The British Society for rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56(7):e1\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1567_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen T, Janssens H, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1567_CR15","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.","journal-title":"PLoS Med"},{"issue":"6","key":"1567_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/10408363.2018.1480591","volume":"55","author":"E English","year":"2018","unstructured":"English E, Lenters-Westra E. HbA1c method performance: the great success story of global standardization. Crit Rev Clin Lab Sci. 2018;55(6):408\u201319.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"5","key":"1567_CR17","doi-asserted-by":"publisher","first-page":"e218505","DOI":"10.1001\/jamanetworkopen.2021.8505","volume":"4","author":"A Zembic","year":"2021","unstructured":"Zembic A, Eckel N, Stefan N, Baudry J, Schulze MB. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw Open. 2021;4(5):e218505.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1567_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FEH Lee Jr","year":"1996","unstructured":"Lee FEH Jr, Mark KL. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361\u201387.","journal-title":"Stat Med"},{"issue":"1","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"e1919666","DOI":"10.1001\/jamanetworkopen.2019.19666","volume":"3","author":"PC Rezende","year":"2020","unstructured":"Rezende PC, Hlatky MA, Hueb W, Garcia RMR, da Silva Selistre L, Lima EG, Garzillo CL, Scudeler TL, Boros GAB, Ribas FF, et al. Association of longitudinal values of glycated hemoglobin with cardiovascular events in patients with type 2 diabetes and multivessel coronary artery disease. JAMA Netw Open. 2020;3(1):e1919666.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1567_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jama.2014.1873","volume":"311","author":"C Emerging Risk Factors","year":"2014","unstructured":"Emerging Risk Factors C, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014;311(12):1225\u201333.","journal-title":"JAMA"},{"issue":"4","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ije\/dyaa263","volume":"50","author":"K Inoue","year":"2021","unstructured":"Inoue K, Nianogo R, Telesca D, Goto A, Khachadourian V, Tsugawa Y, Sugiyama T, Mayeda ER, Ritz B. Low HbA1c levels and all-cause or cardiovascular mortality among people without diabetes: the US National Health and Nutrition Examination Survey 1999\u20132015. Int J Epidemiol. 2021;50(4):1373\u201383.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"1567_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.diabet.2018.01.012","volume":"44","author":"EYF Wan","year":"2018","unstructured":"Wan EYF, Yu EYT, Fung CSC, Chin WY, Fong DYT, Chan AKC, Lam CLK. Relation between HbA1c and incident cardiovascular disease over a period of 6\u2009years in the Hong Kong population. Diabetes Metab. 2018;44(5):415\u201323.","journal-title":"Diabetes Metab"},{"issue":"6","key":"1567_CR23","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1210\/jc.2014-4454","volume":"100","author":"S Liu","year":"2015","unstructured":"Liu S, Hempe JM, McCarter RJ, Li S, Fonseca VA. Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults. J Clin Endocrinol Metab. 2015;100(6):2364\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1567_CR24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384\u201395.","journal-title":"Diabetes Care"},{"issue":"12","key":"1567_CR25","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/dc16-2680","volume":"40","author":"VW Zhong","year":"2017","unstructured":"Zhong VW, Juhaeri J, Cole SR, Kontopantelis E, Shay CM, Gordon-Larsen P, Mayer-Davis EJ. Incidence and Trends in hypoglycemia hospitalization in adults with type 1 and type 2 diabetes in England, 1998\u20132013: a retrospective cohort study. Diabetes Care. 2017;40(12):1651\u201360.","journal-title":"Diabetes Care"},{"issue":"15","key":"1567_CR26","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","volume":"371","author":"S Zoungas","year":"2014","unstructured":"Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392\u2013406.","journal-title":"N Engl J Med"},{"issue":"9","key":"1567_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa0908359","volume":"362","author":"E Selvin","year":"2010","unstructured":"Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800\u201311.","journal-title":"N Engl J Med"},{"issue":"7","key":"1567_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/annrheumdis-2016-210357","volume":"76","author":"M Andres","year":"2017","unstructured":"Andres M, Bernal JA, Sivera F, Quilis N, Carmona L, Vela P, Pascual E. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Ann Rheum Dis. 2017;76(7):1263\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1567_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380\u201390.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"1567_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894\u2013900.","journal-title":"Circulation"},{"issue":"1","key":"1567_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1567_CR32","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.2337\/dc18-0289","volume":"41","author":"SL Au Yeung","year":"2018","unstructured":"Au Yeung SL, Luo S, Schooling CM. The impact of glycated hemoglobin (HbA1c) on Cardiovascular disease risk: a mendelian randomization study using UK biobank. Diabetes Care. 2018;41(9):1991\u20137.","journal-title":"Diabetes Care"},{"issue":"9","key":"1567_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","volume":"186","author":"A Fry","year":"2017","unstructured":"Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. Am J Epidemiol. 2017;186(9):1026\u201334.","journal-title":"Am J Epidemiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01567-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01567-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T11:09:55Z","timestamp":1657883395000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01567-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01567-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The UK Biobank study was approved by the North West Multicenter Research Ethics Committee (11\/NW\/0382). The Guangdong Second General Provincial Hospital Research Ethics Committee approved the current analysis (2022-KY-KZ-119-01).  All participants provided written consent before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participants"}},{"value":"Consent for publication was obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GYHL has served as a consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees have been received directly or personally. All other authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}